Torrent Pharma Recalls Carbamazepine Tablets for Failed Dissolution Specifications
Torrent Pharma Inc. is recalling 6,228 bottles of Carbamazepine 200 mg tablets because they failed to meet dissolution specifications.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which is defined as a situation where use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences. The hazard is a failure to meet dissolution specifications, which is a quality control issue rather than a contamination or mislabeling of a common allergen.
Plain-English summary
Torrent Pharma Inc. is recalling 6,228 bottles of Carbamazepine Tablets, USP 200 mg. The product is packaged in 500-count bottles and is available by prescription only. The specific lot number is 4FF4F001, with an expiration date of 1/2023. The NDC for the recalled product is 13668-268-05.
The recall was initiated because the product failed to meet dissolution specifications. Dissolution is a critical quality attribute that ensures the drug releases its active ingredient at the expected rate in the body. Failure to meet these specifications may result in the medication not working as intended.
The affected product was distributed nationwide in the United States and in Puerto Rico. Consumers and healthcare providers should check their inventory for this specific lot number and expiration date. If the product is found, it should be returned to the pharmacy or healthcare provider for disposal or replacement. Patients should consult their healthcare provider for alternative treatment options if necessary.
The recalled product
- Product
- CARBAMAZEPINE (CARBAMAZEPINE)
- Brand
- CARBAMAZEPINE
- Manufacturer
- Torrent Pharma Inc.
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 6,228
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 4FF4F001
- Exp 1/2023
Distribution
Related recalls
Same brand · CARBAMAZEPINE
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- HighSun Pharmaceutical Recalls Carbamazepine Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2026-08-26
- ModerateCarbamazepine extended release tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-10-08
- ModerateCarbamazepine tablets recalled for failed dissolution specifications
FDA (Drugs) · 2022-01-19
- ModerateCarbamazepine 200mg Tablets Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2021-09-29
Same manufacturer · Torrent Pharma Inc.
See all →- SevereFluoxetine Tablets 20 mg Recalled for N-Nitroso Impurity
FDA (Drugs) · 2025-06-11
- HighFluoxetine Tablets USP 20 mg Recalled for N-Nitroso Contamination
FDA (Drugs) · 2025-06-11
- High
- ModerateTelmisartan and Hydrochlorothiazide Tablets Recalled for Superpotency
FDA (Drugs) · 2021-12-22
- SevereTorrent Pharma Recalls Anagrelide Capsules Due to Failed Dissolution Specifications
FDA (Drugs) · 2020-12-09
Same hazard · failed dissolution
See all →- ModerateNovartis Recalls Diovan Valsartan Tablets Due to Failed Dissolution Specifications
FDA (Drugs) · 2026-08-19
- LowSupernus Recalls Trokendi XR Capsules for Failed Dissolution Specifications
FDA (Drugs) · 2026-07-29
- HighAscend amlodipine and olmesartan tablets failed dissolution specifications
FDA (Drugs) · 2026-06-10
- HighLannett niacin extended-release tablets failed dissolution specifications during stability
FDA (Drugs) · 2026-06-10
- HighMajor Pharmaceuticals memantine extended-release capsules fail dissolution specifications
FDA (Drugs) · 2026-04-22